Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 3venetoclax 2selpercatinib 2obinutuzumab 2ibrutinib 2decitabine and cedazuridine drug combination 2cedazuridine 2Rituximab 2Nivolumab 2Midazolam 2Ipilimumab 2Decitabine 2Crizotinib 2zanubrutinib 1trametinib 1toripalimab 1tocilizumab 1tazemetostat 1tagraxofusp 1sotorasib 1sacituzumab govitecan 1romiplostim 1revumenib 1repotrectinib 1prednisolone phosphate 1prednisolone acetate 1pralsetinib 1polatuzumab vedotin 1pirtobrutinib 1olutasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has announcements × Decitabine × Clear all
NCT04657081 2025-12-08

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
101 enrolled 1 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Astex Pharmaceuticals, Inc.

Phase 1/2 Completed
130 enrolled 34 charts 1 FDA
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡